Gaiero David G 4
4 · Cyteir Therapeutics, Inc. · Filed Feb 7, 2023
Insider Transaction Report
Form 4
Gaiero David G
Vice President, Finance
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2021-12-20−4,100→ 73,639 totalExercise: $1.68Exp: 2030-12-10→ Common Stock (4,100 underlying) - Exercise/Conversion
Common Stock
2021-12-20$1.68/sh+4,100$6,888→ 4,100 total
Footnotes (2)
- [F1]Due to rounding in connection with the Issuer's reverse stock split during its initial public offering, the exercise price for this option was immaterially incorrect as reported on the Reporting Person's Form 3 filing on June 17, 2021, and has been corrected in this Form 4.
- [F2]The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.